Your browser doesn't support javascript.
loading
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.
Moskalenko, Marina; Pan, Michael; Fu, Yichun; de Moll, Ellen H; Hashimoto, Daigo; Mortha, Arthur; Leboeuf, Marylene; Jayaraman, Padmini; Bernardo, Sebastian; Sikora, Andrew G; Wolchok, Jedd; Bhardwaj, Nina; Merad, Miriam; Saenger, Yvonne.
Afiliação
  • Moskalenko M; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Pan M; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Fu Y; Department of Medicine, Columbia University Medical Center, New York, New York.
  • de Moll EH; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Hashimoto D; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
  • Mortha A; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Leboeuf M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Jayaraman P; Department of Otolaryngology, Baylor College of Medicine, Houston, Texas.
  • Bernardo S; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Sikora AG; Department of Otolaryngology, Baylor College of Medicine, Houston, Texas.
  • Wolchok J; Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Bhardwaj N; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Merad M; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Saenger Y; Division of Hematology and Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Department of Medicine, Columbia University Medical Center, New York, New York. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. yms4@cumc.
Cancer Immunol Res ; 3(3): 296-304, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25600438
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Células Matadoras Naturais / Ciclofosfamida / Imunidade Inata / Imunoterapia / Anticorpos Monoclonais Limite: Animals Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2015 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Células Matadoras Naturais / Ciclofosfamida / Imunidade Inata / Imunoterapia / Anticorpos Monoclonais Limite: Animals Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2015 Tipo de documento: Article País de publicação: Estados Unidos